Similar to other antigens (CD33, Her2, EGFR) which are used as therapeutic targets and that are not tumor cell-specific, first in men studies with novel drugs targeting such new target structures have to be carefully performed, and it has to be determined whether a safe therapeutic window exists. This evidence concerns the gene CD33 and neoplasm.